Metabolic Syndrome and HCC. Jacob George

Similar documents
Viral hepatitis and Hepatocellular Carcinoma

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

METABOLIC SYNDROME AND HCV: FROM HCV

Hepatocellular Carcinoma: Epidemiology and Screening

Natural History of Chronic Hepatitis B

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma (HCC): Burden of Disease

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

The role of Hepatitis C Virus in hepatocarcinogenesis

Type 2 Diabetes and Cancer: Is there a link?

/Webpages/zhang/chinese-full full- program.htm

Improving Access to Quality Medical Care Webinar Series

Clinical dilemmas in HBeAg-negative CHB

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Hepatocellular carcinoma

Worldwide Causes of HCC

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C.

UMHS-PUHSC JOINT INSTITUTE

Worldwide Causes of HCC

Liver transplant: what is left after the viruses

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

5. SUMMARY OF DATA. 5.1 Exposure data

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

DM, NAFLD, and conjugated linoleic acid (omega 6); what is the link

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

Natural History of HBV Infection

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Steatosi epatica ed HCV

Liver Pathology in the 0bese

Screening cardiac patients for advanced liver disease

Increased risk of cancer with anti-diabetes drugs? : pros

Table 2.1. Cohort Studies of HCV and Hepatocellular Carcinoma

Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Mortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL

NATURAL HISTORY OF HEPATITIS B

White Nights of Hepatology 2016

NASH Bench to Bedside

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

Microarray Analysis and Liver Diseases

Connecting Links for Reducing Risks: Understanding the impact of obesity on cancer development. Kristi Acker, DNP, FNP-BC, AOCNP, ACHPN

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Incidence of Primary Liver Cancer in American Indians and Alaska Natives

T he incidence of hepatocellular carcinoma (HCC) has

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

Fatty liver disease: What do we know?

Hepatocellular Carcinoma Surveillance

NAFLD & NASH: Russian perspective

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Programs for Chronic HBV and HCV in Alaska Natives

NONALCOHOLIC FATTY LIVER DISEASE

Type 2 Diabetes in Native Hawaiians according to Admixture: The Multiethnic Cohort

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Don t interfere My first choice is always nucs!

Hepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Cancer Key facts The problem Cancer causes

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Host Factors that Increase Breast Cancer Risk

Screening for HCCwho,

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

The place of bariatric surgery in NASH: can we extend the indications? - No

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME

Management of Decompensated Chronic Hepatitis B

Hepatitis B screening and surveillance in primary care

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

5. Summary of Data Reported and Evaluation

The Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS

Non-Alcoholic Fatty Liver Disease

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

What you need to know about liver disease

Low-Carbohydrate Diets and All-Cause and Cause-Specific Mortality: A Population-based Cohort Study and Pooling Prospective Studies

Transcription:

Metabolic Syndrome and HCC Jacob George

MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For comparison, a 5% sample of individuals residing in the same regions as the SEER registries of the cases was selected 3649 HCC cases, 743 ICC cases, and 195,953 comparison persons Welzel T et al; HEPATOLOGY 2011;54:463-471

900,053 subjects from the American Cancer Society s Cancer Prevention Study II. Average age at enrollment was 57 years. Baseline weight and height, plus smoking status, race, level of education attained, exercise, dietary information, medications, alcohol intake. After 16 years of follow up, 32,303 deaths from cancer with detailed information on diagnosis for 98.8%.

Morbid obesity and death due to cancers Calle et al NEJM 2003

Morbid obesity and death due to cancers Calle et al NEJM 2003

Diabetes and HCC Hospital discharge with diabetes between 1985 and 1990 VA. 3 patients without diabetes for every patient with diabetes. Excluded patients with concomitant liver disease and followed to 2000 173,643 patients with diabetes and 650,620 patients without diabetes. 98% men Diabetes was associated with an HRR of 1.98 (95% CI: 1.88 to 2.09, P < 0.0001) of CNLD and an HRR of 2.16 (1.86 to2.52, P < 0.0001) of HCC Diabetes carried the highest risk among patients with >10 years follow-up. Cirrhosis HCC El-Serag et al; GASTROENTEROLOGY 2004;126:460 468

Is the substrate for NAFLD- HCC increasing in Asia Pacific

National obesity trends

T2DM trends

NAFLD Prevalence in A-P Mahady S et al, JCEH

Substrate for NAFLD-HCC is increasing in Asia Pacific: Why?

Stages of the nutrition transition Mahady S et al adapted from Popkin BM, et al, Int J Ob & Rel Metab Disord 2004;28 Suppl 3:S2-9

Does MetS contribute to viral HCC

Cirrhosis and MetS, DM N=1466, CHB LSM>8.4 LSM>13.4 CHC G L-H Wong, Gut 2009;58:111 117; Veldt et al HEPATOLOGY 2008;47:1856-1862

NASH as a cofactor in HCC 23,820 residents in Taiwan; followed 14 y. BMI >30 kg/m2 associated with 4-fold risk of HCC (RRa, 4.13; 95% CI, 1.38 12.4) among HCV+; and 2- fold risk (RRa, 2.36; 95% CI, 0.91 6.17) without HBV and HCV infections, after controlling for other metabolic components, but not in HBsAg positive (RRa, 1.36; 95% CI, 0.64 2.89). DM associated with HCC, with risk in those with HCV (RRa, 3.52; 95% CI, 1.29 9.24) and in HBV (RRa, 2.27; 95% CI, 1.10 4.66). >100-fold increased risk in HBV or HCV carriers with both obesity and diabetes Chen et al; GASTROENTEROLOGY 2008;135:111 121

NASH as a cofactor in HCC Chen et al; GASTROENTEROLOGY 2008;135:111 121

Clinical features of NASH- HCC

Clin Features: NASH related HCC Yasui et al CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:428 433

Pathology of mets HCC MetS HCC developed in older patients mean age (67 +/-7 versus 59 +/- 14 years, P < 0.01) 5/31 developed in pre-existing liver cell adenoma, with three showing histological features of telangiectatic adenoma Paradis et al, HEPATOLOGY 2009;49:851-859

Pathogenesis

Obesity, Inflammatory Signaling, and HCC Toffanin S et al; Cancer Cell 17, February 17, 2010

Inflammation Obesity and the metabolic syndrome are associated with a pro-inflammatory state: Elevated CRP, ferritin, IL-6 and TNF Inflammation is recognised to be a driver of tumour growth, supplying growth factors, proangiogenic factors and matrix remodelling enzymes that promote invasion. The generation of reactive oxygen species is an additional effect leading to chromosomal damage. Sustaining proliferative signaling, activating invasion and resisting cell death

Insulin- IGF1 axis Hyperinsulinemia: Has pro-mitotic and anti-apoptotic activity Has been shown to promote aberrant crypt foci in the colon Promotes growth of colon cancer cells in vitro Human colorectal adenocarcinomas express IR at high levels IGF-1 has stronger pro-mitotic and anti-apoptotic activity than insulin Some studies have shown positive associations with circulating IGF-1 levels and colorectal cancer incidence. Sustaining proliferative signaling and resisting cell death From: Gunter et al (2008) Cancer Res

Adiponectin The most abundant fat derived hormone Levels are inversely related to body mass ie. Obesity is associated with low adiponectin Adiponectin: Has anti-inflammatory properties Has been shown to reduce proliferation of various cancer cells in vitro including liver tumour cells, colorectal cancer cells Low levels in humans are associated with increased risks of endometrial cancer, breast cancer and colorectal cancer.

Animal models of HCC in NAFLD HCC induced in wild type (WT) and adiponectin knockout (ADN KO) mice using the carcinogen diethylnitrosamine (DEN) Liver and tumour tissue was fixed for histology and snap frozen for gene and protein expression. Tumour volume was estimated by measuring the surface diameter and calculating : Vol = 4/3 πr 3

Adiponectin KO mice have bigger tumours

PI3K-Akt-mTOR pathway From: Chen, J (2011) Obesity Reviews

VAT and cancer R. Vongsuvanh et al; Cancer Letters 330 (2013) 1 10

VAT and cancer R. Vongsuvanh et al; Cancer Letters 330 (2013) 1 10

Metformin and HCC risk 97 430 HCC patients and 194 860 age-, gender- and physician visit date-matched controls Gut 2013;62:606 615. doi:10.1136/gutjnl-2011-3017

MetS and HCC Poor data across the region with variations in quality HBV-HCC will dramatically decline with vaccination HCV-HCC will begin to decline with newer therapies once treatment is affordable Diabesity will become a major cause of HCC Diabesity will be an important co-factor for viral hepatitis associated HCC Outcomes highly variable depending on country

Acknowledgements